GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sequent Scientific Ltd (NSE:SEQUENT) » Definitions » Current Ratio

Sequent Scientific (NSE:SEQUENT) Current Ratio : 1.70 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sequent Scientific Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sequent Scientific's current ratio for the quarter that ended in Sep. 2024 was 1.70.

Sequent Scientific has a current ratio of 1.70. It generally indicates good short-term financial strength.

The historical rank and industry rank for Sequent Scientific's Current Ratio or its related term are showing as below:

NSE:SEQUENT' s Current Ratio Range Over the Past 10 Years
Min: 0.72   Med: 1.43   Max: 2.21
Current: 1.7

During the past 13 years, Sequent Scientific's highest Current Ratio was 2.21. The lowest was 0.72. And the median was 1.43.

NSE:SEQUENT's Current Ratio is ranked worse than
56.47% of 1036 companies
in the Drug Manufacturers industry
Industry Median: 1.97 vs NSE:SEQUENT: 1.70

Sequent Scientific Current Ratio Historical Data

The historical data trend for Sequent Scientific's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequent Scientific Current Ratio Chart

Sequent Scientific Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.42 1.55 1.53 1.41 1.31

Sequent Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 - 1.31 - 1.70

Competitive Comparison of Sequent Scientific's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sequent Scientific's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequent Scientific's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sequent Scientific's Current Ratio distribution charts can be found below:

* The bar in red indicates where Sequent Scientific's Current Ratio falls into.



Sequent Scientific Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Sequent Scientific's Current Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Current Ratio (A: Mar. 2024 )=Total Current Assets (A: Mar. 2024 )/Total Current Liabilities (A: Mar. 2024 )
=8228.56/6269.9
=1.31

Sequent Scientific's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=8289.5/4887.9
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sequent Scientific  (NSE:SEQUENT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Sequent Scientific Current Ratio Related Terms

Thank you for viewing the detailed overview of Sequent Scientific's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequent Scientific Business Description

Traded in Other Exchanges
Address
Plot No. E7, Road No. 22, 301, 3rd Floor, Dosti Pinnacle, Wagle Industrial Estate, Thane (West), Mumbai, MH, IND, 400 604
Sequent Scientific Ltd is a pharmaceutical company operating animal health and analytical services. It develops API products and formulations. The company's product portfolio includes products across various therapy classes such as antibiotics, anthelmintics, pain management, and nutrition. The company's geographical segment includes Europe, Asia, and Rest of the world. It generates maximum revenue from Europe.

Sequent Scientific Headlines

No Headlines